Law360, New York (February 23, 2009) -- The epilepsy drug zonisamide — marketed under the brand name Zonegran by Eisai Co. Ltd. and sold in generic form by Teva Pharmaceutical Industries Ltd., Mylan Inc., Novartis AG’s Sandoz unit and Watson Pharmaceuticals Inc. — has come under fire by federal health regulators, who warned Monday the medication can cause a serious blood disorder known as metabolic acidosis in some patients.
The U.S. Food and Drug Administration said it had made the determination following a review of updated clinical data related to zonisamide, which is indicated as adjunctive therapy in the...
